10.03.18
Zosano Pharma Corporation announced a manufacturing and supply agreement for M207 with a leading global contract development and manufacturing organization, which serves more than 400 clients in the pharmaceutical and biotechnology sectors.
Under the terms of the agreement, Zosano will transfer its proprietary technology for the coating of zolmitriptan onto the ADAM delivery system. Additionally Zosano has entered into a long-term manufacturing and supply agreement.
“This agreement represents another step in our overall strategy to commercialize M207, when and if approved by the Food and Drug Administration,” said John Walker, chief executive officer and chairman of the board of Zosano Pharma. “The decision to contract with an outside manufacturer enables Zosano to focus its current manufacturing capability for the supply of clinical trial material for future development programs. We believe this will result in our conservation of capital, improved cost of goods and ensured availability of supply once M207 is launched.”
Under the terms of the agreement, Zosano will transfer its proprietary technology for the coating of zolmitriptan onto the ADAM delivery system. Additionally Zosano has entered into a long-term manufacturing and supply agreement.
“This agreement represents another step in our overall strategy to commercialize M207, when and if approved by the Food and Drug Administration,” said John Walker, chief executive officer and chairman of the board of Zosano Pharma. “The decision to contract with an outside manufacturer enables Zosano to focus its current manufacturing capability for the supply of clinical trial material for future development programs. We believe this will result in our conservation of capital, improved cost of goods and ensured availability of supply once M207 is launched.”
